Back to Search
Start Over
Randomized trial experience of the Intergroupe Francophone du MyƩlome.
- Source :
-
Seminars in hematology [Semin Hematol] 2001 Jul; Vol. 38 (3), pp. 226-30. - Publication Year :
- 2001
-
Abstract
- This article summarizes clinical results of the Intergroupe Francophone du Myélome (IFM) trials: high-dose therapy (HDT) supported with autologous stem cells improves survival, melphalan 200 mg/m(2) is the best preparative regimen, unpurged peripheral blood stem cells (PBSC) are the recommended source of stem cells to support HDT, and tandem transplants significantly improve survival. Although these results are encouraging, the current IFM 99 protocol will evaluate innovative strategies with the goal to improve long-term survival.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols administration & dosage
Combined Modality Therapy
Humans
Melphalan administration & dosage
Melphalan therapeutic use
Multiple Myeloma mortality
Randomized Controlled Trials as Topic
Survival Analysis
Transplantation, Autologous
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Hematopoietic Stem Cell Transplantation
Multiple Myeloma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0037-1963
- Volume :
- 38
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Seminars in hematology
- Publication Type :
- Academic Journal
- Accession number :
- 11486310
- Full Text :
- https://doi.org/10.1016/s0037-1963(01)90014-9